The Expanding RAS-Directed Pipeline in Pancreatic Cancer

Shubham Pant, MD, MBBS, discusses the rapidly growing pipeline of RAS-directed agents for patients with pancreatic cancer, building on the momentum of the recent FDA approval of daraxonrasib (Rasonque), a pan-RAS inhibitor for metastatic pancreatic ductal adenocarcinoma (mPDAC).

For decades, RAS mutations, which are present in the large majority of pancreatic adenocarcinomas, were considered undruggable. This left cytotoxic chemotherapy as the dominant systemic option despite modest outcomes. Pant frames the daraxonrasib approval as a launching point in a fast-expanding class of RAS-directed agents now moving through clinical development. He points specifically to additional RAS(ON) inhibitors and pan-RAS inhibitors, which target multiple RAS mutations simultaneously, as well as allele-specific KRAS G12D inhibitors designed to act against one of the most common oncogenic drivers seen in pancreatic adenocarcinoma.

Several of these emerging agents are being evaluated alongside standard chemotherapy backbones or paired with other novel targeted agents, including daraxonrasib itself, suggesting that RAS-directed treatment in pancreatic cancer is moving toward combination-based strategies rather than single-agent approaches alone.

For example, treatment with the oral RAS(ON) G12D-selective covalent inhibitor zoldonrasib led to substantial response rates in patients with mPDAC when combined with chemotherapy in the first-line setting and with daraxonrasib in the second-line setting, according to phase 1/2 data presented at the 2026 European Society for Medical Oncology Gastrointestinal Cancers Congress. Building on these positive findings, the ongoing phase 3 RASolute 305 trial (NCT07621718) is evaluating zoldonrasib plus chemotherapy versus chemotherapy alone in patients with previously untreated metastatic RAS G12D–mutated PDAC.

As more RAS-directed agents generate clinical data, biomarker testing to identify specific RAS alterations, including G12D and other common variants, is likely to become increasingly relevant to treatment selection and sequencing decisions. Clinical trial enrollment is also likely to take on greater importance as a treatment pathway, given how many of these agents remain in active investigation.